Kcentra Dosing for Preoperative Anticoagulation Reversal
For a 61 kg, 56-year-old male requiring urgent surgery, the Kcentra dose depends critically on the pre-procedure INR value: if INR is unknown or unavailable, administer 25 IU/kg (1,525 units Factor IX) along with 5 mg IV vitamin K; if INR is 2-<4, use 25 IU/kg (1,525 units); if INR is 4-6, use 35 IU/kg (2,135 units); if INR is >6, use 50 IU/kg (3,050 units). 1
Dosing Algorithm Based on INR
The FDA-approved Kcentra dosing is weight-based and INR-stratified 1:
For this 61 kg patient:
- INR 2 to <4: 25 units/kg = 1,525 units Factor IX
- INR 4 to 6: 35 units/kg = 2,135 units Factor IX
- INR >6: 50 units/kg = 3,050 units Factor IX
When INR is Unavailable
If surgery must proceed immediately without INR results available, administer 25 IU/kg (1,525 units) with 5 mg IV vitamin K, proceed with surgery, and check INR within 30 minutes. If the hemostatic safety threshold (INR ≤1.5, or ≤1.2 for neurosurgery) is not met, consider supplementary dosing. 2
Essential Concurrent Management
Always administer vitamin K concurrently with Kcentra to maintain vitamin K-dependent clotting factor levels once Kcentra's effects diminish. 1 The 2024 ERAS Cardiac Society guidelines recommend Kcentra at 0.12 mL/kg/min IV titrated to goal INR for emergent DOAC reversal, though this patient's scenario involves preoperative VKA reversal. 3
Timing and Monitoring Considerations
- Measure INR as close to dosing time as possible - coagulation factors may be unstable in patients requiring urgent procedures 1
- Target INR ≤1.5 for most surgeries, ≤1.2 for intracranial neurosurgery or neuraxial procedures 2
- Monitor INR within 30 minutes post-administration - clinical trials showed Kcentra decreased INR to ≤1.3 within 30 minutes in most subjects 1
- Check INR before the procedure to confirm hemostatic safety threshold is achieved 2
Important Safety Considerations
Thrombotic Risk
This patient's underlying condition requiring anticoagulation creates inherent thrombotic risk. Weigh the benefits of VKA reversal against thromboembolic event risks, especially if there is history of recent thromboembolism (<3 months). 1 Kcentra was not studied in patients with thromboembolic events, MI, CVA, TIA, or unstable angina within 3 months prior. 1
Recent pharmacovigilance data (2.3 million infusions) showed TEE rates of approximately 1 per 9,963 standard infusions, with most cases having pre-existing thrombotic risk factors. 4
Repeat Dosing
Repeat dosing is not recommended - safety and effectiveness have not been established. 1 Less than 5% of patients require repeat doses with appropriate initial dosing. 5
Weight Considerations
At 61 kg, this patient is well below the 100 kg dosing cap. Do not use adjusted body weight - actual body weight dosing achieves superior INR reversal compared to adjusted weight strategies. 6 The 100 kg maximum dose cap only applies to patients exceeding that weight. 1
Clinical Context: Warfarin vs. DOAC
This dosing applies specifically to vitamin K antagonist (warfarin) reversal. If this patient is on a DOAC instead:
- For Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban): Consider andexanet alfa as first-line if available; if unavailable, use 4F-PCC 25-50 IU/kg 7, 8
- For dabigatran: Use idarucizumab 5g IV as specific reversal agent 9
Practical Administration
After calculating the dose, reconstitute Kcentra with provided Sterile Water for Injection (20 mL for 500 U kit, 40 mL for 1000 U kit) using the Mix2Vial transfer system. 1 The actual potency per vial (stated on carton) varies from 20-31 Factor IX units/mL after reconstitution, so verify the volume needed based on actual vial potency.
For this 61 kg patient requiring 1,525 units (at INR 2-<4), using a vial with 30 units/mL potency, administer approximately 51 mL.